

CCR4highCD4+ Cell populations in Kidney Graft Blood after Steroid Withdrawal: a prospective, randomized, controlled, parallel group study. Preliminary results

Authors: Alonso-Titos J, MD¹, Ruiz-Esteban P, MSc, PhD¹, Palma E, MSc¹, Caballero A, MD, PhD², Lopez V, MD, PhD¹, Sola E, MD¹, Cabello M, MD,PhD¹, Vazquez T, MD¹, Duarte A, MD¹, Jironda C, MD, PhD¹, Hernandez D, MD, PhD¹.

¹Nephrology and ²Immunology Departments, Regional University Hospital, IBIMA, REDINREN (RD16/0009/0006), ICI14/00016, University of Malaga (Spain).





Steroids represent a mainstay of immunosuppression after kidney transplant (KT). The infiltration into the

•Controlled clinical trial (NCT02284464).

graft of active T cells following KT depends on the

expression of chemokines and their interaction with

their T-cell receptors. However, the natural history of

the expression of these molecules in patients who undergo steroid withdrawal after transplant is unknown.



So far, 68 patients have been randomized (34 in each

•Patients: 176 KT patients with low immunological risk.

•Randomized at 3 months post-KT:

•Group A: steroids, TAC and MMF.

•Group B: steroid withdrawal at the third post-KT month.

•Lymphocyte subpopulations: CCR4highCD4+ and CXCR3highCD4+.

•Aim: To compare the evolution of CCR4highCD4+ and CXCR3highCD4+ lymphocyte subpopulations in graft blood (GB)

extracted by fine needle aspiration puncture determined by flow

cytometry in patients after steroid withdrawal at the 3 month post-

KT (Group B) versus patients who continue to receive conventional

triple immunosuppression (Group A).

•Measurements at 3 (baseline) and 6 months post-KT in GB and in

group). There were no significant differences in the

clinical and demographic characteristics between the

groups at baseline. The first analysis (at 3 months) in

those patients who had completed 6 months of follow-

up (Group A: n=13; Group B: n=15) showed a significant

increase in the CCR4highCD4+ subpopulations in GB

versus PB in both groups. However, at six months a

significant increase in GB versus PB was only seen in

Group A. There were no significant differences in the

CXCR3highCD4+ lymphocyte subpopulation at the third

or sixth month between GB and PB in either group

peripheral blood (PB).

Evolution of CCR4highCD4+ CXCR3highCD4+ Table and 1. lymphocyte subpopulations.

	Group A			Group B		
	PB	GB	Р	PB	GB	Р
CCR4highCD4+ (%)						
3 months	0.40 ± 0.34	2.28±2.46	0.001	0.45±0.64	2.09±3.84	0.003
6 months	0.42±0.57	2.97±5.35	0.023	0.71±0.81	1.27±1.43	0.117
CXCR3highCD4+ (%)						
3 months	0.78 ± 1.54	$0.82{\pm}1.30$	0.950	0.72±1.34	0.50±0.92	0.567
6 months	0.99±1.73	1.63±4.64	0.423	2.82±4.70	$1.05{\pm}1.55$	0.063

Group A: Tacrolimus+MMF+steroids; Group B: Tacrolimus+MMF; PB: peripheral blood; GB: graft blood.



These preliminary results could suggest a possible effect of prednisone that would favor the recruitment of CCR4highCD4+ cells into the renal graft. The effect of prednisone on the CCR4highCD4+ tolerogenic subpopulations is unknown. Additional studies are needed to determine the role of prednisone in these tolerogenic subpopulations in the renal graft.



(Table).



736--SP Renal transplantation - Epidemiology & outcome I

ERA

Juana Alonso-Titos





DOI: 10.3252/pso.eu.54ERA.2017